• Home
  • Search Results
  • Pancreatic cancer triggers diabetes through TGF-β-mediated selective depletion of islet β-cells.

Pancreatic cancer triggers diabetes through TGF-β-mediated selective depletion of islet β-cells.

Life science alliance (2020-05-07)
Parash Parajuli, Thien Ly Nguyen, Céline Prunier, Mohammed S Razzaque, Keli Xu, Azeddine Atfi

Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease that remains incurable because of late diagnosis, which renders any therapeutic intervention challenging. Most PDAC patients develop de novo diabetes, which exacerbates their morbidity and mortality. How PDAC triggers diabetes is still unfolding. Using a mouse model of KrasG12D-driven PDAC, which faithfully recapitulates the progression of the human disease, we observed a massive and selective depletion of β-cells, occurring very early at the stages of preneoplastic lesions. Mechanistically, we found that increased TGF beta (TGF-β) signaling during PDAC progression caused erosion of β-cell mass through apoptosis. Suppressing TGF-β signaling, either pharmacologically through TGF-β immunoneutralization or genetically through deletion of Smad4 or TGF-β type II receptor (TβRII), afforded substantial protection against PDAC-driven β-cell depletion. From a translational perspective, both activation of TGF-β signaling and depletion of β-cells frequently occur in human PDAC, providing a mechanistic explanation for the pathogenesis of diabetes in PDAC patients, and further implicating new-onset diabetes as a potential early prognostic marker for PDAC.

Product Number
Product Description

Pyrvinium pamoate salt hydrate, ≥98% (HPLC)
Tamoxifen, ≥99%
Transforming Growth Factor-β1 human, TGF-β1, recombinant, expressed in CHO cells, powder, suitable for cell culture
Caerulein, ≥95% (HPLC)
Ponceau S solution, BioReagent, suitable for electrophoresis, 0.1 % (w/v) in 5% acetic acid
Monoclonal Anti-Glucagon antibody produced in mouse, clone K79bB10, ascites fluid